RALEIGH, N.C., Nov. 23, 2016 /PRNewswire/ -- BioDelivery
Sciences International, Inc. (NASDAQ: BDSI) announced that Dr.
Mark A. Sirgo, President and Chief
Executive Officer, will present at the 28th Annual Piper
Jaffray Healthcare Conference.
The presentation, which will be webcast, is scheduled for
Wednesday, November 30, at
2:00 PM Eastern Time at the Lotte New
York Palace Hotel in New York
City.
The presentation will be webcast live and can be accessed at
www.bdsi.com. For those who are not available to listen to
the live broadcast, replay of the webcast will be available on the
BDSI website.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a
specialty pharmaceutical company with a focus in the areas of pain
management and addiction medicine. BDSI is utilizing its
novel and proprietary BioErodible MucoAdhesive (BEMA®)
technology and other drug delivery technologies to develop and
commercialize, either on its own or in partnership with third
parties, new applications of proven therapies aimed at addressing
important unmet medical needs.
BDSI's development strategy focuses on the utilization of the
FDA's 505(b)(2) approval process. This regulatory pathway creates
the potential for more timely and efficient approval of new
formulations of previously approved therapeutics.
BDSI's area of focus is the development and commercialization of
products in the areas of pain management and addiction. These are
areas where BDSI believes its drug delivery technologies and
products can best be applied to address critical unmet medical
needs. BDSI's marketed products and those in development
address serious and debilitating conditions such as breakthrough
cancer pain, chronic pain, painful diabetic neuropathy and opioid
dependence. BDSI's headquarters is in Raleigh, North
Carolina.
For more information,
please visit or follow us:
|
Internet:
|
www.bdsi.com
|
Facebook:
|
Facebook.com/BioDeliverySI
|
Twitter:
|
@BioDeliverySI
|
BUNAVAIL® (buprenorphine and naloxone) buccal film
(CIII) is marketed in the U.S. by BioDelivery Sciences.
BELBUCA® (buprenorphine) buccal film (CIII) is
commercialized in the U.S. by Endo Pharmaceuticals pursuant to the
worldwide licensing and development agreement between BDSI and
Endo. ONSOLIS® (fentanyl buccal soluble film)
(CII) is licensed in the U.S. to Collegium Pharmaceutical pursuant
to the U.S. licensing and development agreement between BDSI and
Collegium. For full prescribing information and important safety
information on BDSI products, including BOXED WARNINGS for ONSOLIS,
please visit www.bdsi.com where the Company promptly
posts press releases, SEC filings and other important information
or contact the Company at (800) 469-0261. For full
prescribing and safety information on BELBUCA, please visit
www.belbuca.com.
Cautionary Note on Forward-Looking Statements
This press release, the presentation described herein, and any
statements of employees, representatives and partners of
BioDelivery Sciences International, Inc. (the "Company") related
thereto contain, or may contain, among other things, certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such
forward-looking statements involve significant risks and
uncertainties. Such statements may include, without
limitation, statements with respect to the Company's plans,
objectives, projections, expectations and intentions and other
statements identified by words such as "projects," "may," "will,"
"could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "potential" or similar
expressions. These statements are based upon the current
beliefs and expectations of the Company's management and are
subject to significant risks and uncertainties, including those
detailed in the Company's filings with the Securities and Exchange
Commission. Actual results (including, without limitation,
the results of commercialization efforts for the Company's approved
products and the clinical trials for, and regulatory review of, the
Company's products in development) may differ significantly from
those set forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
BDSI®, BEMA®, ONSOLIS® and
BUNAVAIL® are registered trademarks of BioDelivery
Sciences International, Inc. The BioDelivery Sciences and
BUNAVAIL logos are trademarks owned by BioDelivery Sciences
International, Inc. BELBUCA® is a trademark owned by Endo
Pharmaceuticals. All other trademarks and tradenames are
owned by their respective owners.
© 2016 BioDelivery Sciences International, Inc. All rights
reserved.
Logo -
http://photos.prnewswire.com/prnh/20110217/CL49801LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biodelivery-sciences-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-300367711.html
SOURCE BioDelivery Sciences International, Inc.